
---

## ðŸ§¬ Genetics Summary

Findings indicate slowed **Phase II estrogen metabolism** (COMT-Met, UGT1A1*28, SULT1E1 variant) and **reduced CYP3A4/5 throughput** (CYP3A4*22 + CYP3A5*3).  
These variants together predispose to **higher circulating estradiol**, **greater catechol load under stress**, and **heightened sensitivity to methylation and histamine burden**.

For details, see: `docs/genetics.md`.


---

## Genetics
Variants indicate **slower estrogen clearance** (CYP3A4*22 Â± CYP3A5*3) and **reduced Phase II conjugation** (UGT1A1*28, SULT1E1 var) with **COMT Val158Met** influencing catechol handling.  
See `docs/genetics.md` for tables and interpretation.
